Summary
- HHS substituted a non-enforcement directive for the formal peptide regulation HHS first sought, after FDA officials warned that the agency’s scientific staff would not support deeming the substances safe, according to two people familiar with the discussions.
- Six people familiar with the policy’s development said most FDA scientific staff opposed the plan and had limited input in drafting it.
- Health Secretary Robert F Kennedy Jr, who has called himself a “big fan” of peptides, has said US compounding pharmacies must be allowed to sell peptides because Americans are turning to “gray market” products imported from China and other countries.
- FDA staff guardrails included in the plan require compounders to source ingredients from FDA-registered facilities, verify the chemical identity of peptides, and collect side-effect information, according to two people familiar with the process.
- The directive does not reach the online channel through which many peptide users order vials from chemical manufacturers based in China under “for research use only” labels, the article reports.
The Department of Health and Human Services posted a policy document online on Wednesday directing the Food and Drug Administration not to take action against specialty pharmacies that sell a half-dozen wellness peptides, including BPC-157, TB-500 and KPV. Under FDA rules those chemicals would otherwise be considered illegal drugs because they have not gone through the agency’s review process for safety and effectiveness. HHS adopted that instrument only after its preferred approach failed: two people familiar with the discussions said HHS officials initially sought a formal regulation adding the peptides to a list of drug substances deemed safe for use by compounding pharmacies, FDA officials warned that the agency’s scientific staff had major safety concerns and “would not support a regulation deeming them safe,” and the department moved instead to directing the FDA not to enforce its rules against pharmacies that compound the substances. The posted document therefore stops short of a deemed-safe finding, the peptides it covers still have not been approved as safe and effective by the FDA, and it is best read as a safe harbor grounded in enforcement discretion rather than in a scientific determination. Six people familiar with the policy’s development, speaking on condition of anonymity to discuss confidential government deliberations, said most FDA scientific staff opposed the plan and had limited input in drafting it, and described “overwhelming pushback among FDA drug staffers” who warned the effort could undermine “the agency’s longstanding mission of keeping unproven health products off the US market.” An HHS spokesperson did not immediately respond to a request for comment. Health Secretary Robert F Kennedy Jr, who has called himself a “big fan” of peptides and has described using BPC-157 to treat a muscle injury, has said US compounding pharmacies must be allowed to sell peptides because Americans are turning to “gray market” products imported from China and other countries.
What explains the policy’s form
The reporting supports three competing explanations for the directive’s existence, to different degrees. The first is statutory and institutional. Federal law “technically gives HHS authority over essentially all drug regulations, which are then delegated to the FDA,” and former FDA officials said “it is extremely rare for HHS to take the lead” in drafting policies over the compounding industry, the article reports. Under this explanation the root cause is a parent department exercising authority it ordinarily delegates, over the objection of the subordinate agency’s scientists, and settling on the least procedurally demanding instrument available — one that does not require the scientific affirmation a rule-making would require. The reported sequence supports this chain: HHS pursued the formal route, was told the scientific staff would not support it, and changed instruments rather than abandon the objective. This chain best explains the policy’s form.
The second explanation is demand and enforcement reach. Peptide use, the article reports, grew into a market that enforcement was not containing: sellers “often try to skirt US regulations by labeling their products ‘for research use only,’” and many consumers order vials directly from chemical manufacturers based in China because the FDA does not regulate research chemicals. Under this chain the root cause is a regulatory dead zone — a product category with genuine demand, no approval pathway being used, and an enforcement posture that could not reach the dominant distribution channel. HHS’s stated rationale is an articulation of this chain: it explains the policy’s salience rather than its form.
The third explanation, industry influence, is under-determined. The policy’s effect aligns with the commercial interests of compounding pharmacies and with the Secretary’s publicly stated position, but the reporting documents no contacts, payments, or other conduits of influence between the industry and the department. Under the sourced record, that alignment stands as a feature of the environment, not a demonstrated cause.
Distinct from root causes, several factors amplified the outcome without generating it: the 2012 outbreak, after which the article reports compounding safety became a greater focus for the FDA; the industry’s growth into a multibillion-dollar business; the research-use labeling loophole; the 2023 FDA list; and the Secretary’s public statements, which supplied the policy’s stated rationale.
Who benefits
The interests arrayed around the policy comprise some the participants have stated and some implied by the market structure the policy regulates.
Kennedy and HHS hold an identity-and-recognition interest: the Secretary has called himself a “big fan” of peptides and has described using BPC-157 to treat a muscle injury, and the policy is consistent with that public stance. The department has an articulated substantive interest in redirecting peptide commerce away from unregulated imports, expressed in the claim that compounding pharmacies must be allowed to sell peptides because Americans are turning to “gray market” products. A procedural interest is also visible: the non-enforcement instrument “avoids a direct confrontation with FDA staff,” and the design spares the scientists from affirming the products’ safety. The article does not document any constituency-related motivation beyond the stated rationale, and none is attributed here.
FDA scientific staff hold a substantive safety interest grounded in the 2012 outbreak and the 2023 designation, and an institutional-mission interest reflected in the warning about keeping unproven products off the US market. The reporting’s central fact about the process is procedural: staff had “limited input” in drafting the policy. A further interest the staff would not necessarily articulate as such is preservation of scientific review as the gate for safety designations — the directive’s design specifically avoids requiring that determination, which is the clearest evidence the interest is in play.
Compounding pharmacies hold an economic interest in lawful access to a profitable and growing category; a regulatory-predictability interest, since a directive not to enforce is a weaker and more reversible basis than the formal regulation HHS originally sought; and a relational interest, since the sourcing and verification guardrails keep participating pharmacies inside the FDA’s regulatory relationship rather than outside it.
Peptide users hold an access interest — many “often order vials online from chemical manufacturers based in China” under “for research use only” labels, a market the policy does not reach; a safety interest, which the side-effect collection requirement is meant to serve; and a fairness-perception interest, because under current labeling whether a product receives oversight depends on the channel through which it is sold rather than on what it is.
Drug companies with approved peptides — the article documents an approved market of “mainstay treatments for diabetes and weight loss” — hold a market-structure interest in the approval standard remaining meaningful; the article does not document any conduct by those companies regarding this policy.
Online sellers and Chinese manufacturers hold an economic interest in the research-use loophole the article describes; the directive does not extend to their channel.
What happens next
The legal backdrop against which the directive operates: under FDA rules the covered chemicals would otherwise be considered illegal drugs; in 2023 the FDA added more than a dozen peptides, including BPC-157 and TB-500, to its list of substances that “should not be compounded because of risks of allergic reactions, kidney damage and tumor growth”; and at a July meeting — the article supplies no year for it — FDA staff reiterated that more than a half-dozen peptides brought forward for reconsideration “remained unproven in terms of safety and effectiveness.” The institutional reference point is the 2012 failure: a deadly “outbreak of fungal meningitis in 2012” was linked to contaminated injections from a Massachusetts compounding pharmacy, after which compounding safety became a greater focus for the FDA, and compounding has since grown into a “multibillion-dollar industry.”
In the near term, the directive shifts the competitive structure of the peptide market: a lawful channel for compounding pharmacies now runs alongside the still-unregulated research-use channel, and the two rest on different legal footings.
In the medium term, the consequence depends on the side-effect data. If collection and analysis function, the policy produces the evidentiary base for the formal regulation HHS first sought. If they do not, the non-enforcement directive leaves the department and the agency exposed to the failure the 2012 outbreak institutionalized the FDA against.
Over the longer term, the question the policy does not reach is whether the compounds themselves meet the safety standard the FDA exists to apply — a question that a directive not to enforce can neither ask nor answer.
Vulnerabilities in the directive’s design
The directive’s principal exposure is its channel boundary. It covers pharmacies, while the online “for research use only” market sits outside its terms. A pharmacy safe harbor can be exploited as a transfer of apparent legitimacy: products sold through a compounding counter gain a regularity the policy does not confer, since the covered peptides still have not been approved as safe and effective. The ingredient-sourcing guardrail acknowledges the supply chain as the exploitation surface. The design could address this with an explicit statement that the directive is not a safety finding, and by applying the sourcing and identity-verification requirements across every channel that compounds or sells the covered peptides.
A second exposure is instrument reversibility. Enforcement discretion is the policy of the current department, not a rule: it can be rescinded, it does not bind state regulators, and it does not alter civil liability exposure. Pharmacies relying on the directive accept less stability than the formal regulation HHS originally sought. If durability is the objective, the alternative path is rule-making with the scientific guardrails embedded in the record; if the objective is a deliberately limited risk tolerance, that could be stated as such with a review trigger.
The side-effect collection requirement is a safety control whose performance depends on submission, analysis, and response, and the article does not document a mechanism for any of the three. If reporting is discretionary or under-resourced, the control reproduces the information gap that the 2012 outbreak exposed — compounding safety became a greater focus for the FDA only after the outbreak. The safe harbor could be conditioned on mandatory adverse-event reporting, with non-submission reinstating enforcement.
The dissent is already public: six people familiar with the policy’s development described the staff opposition and its limited role in drafting, so the directive’s safeguard against confrontation — not requiring scientists to sign off — does not prevent the confrontation from being reported. A future adverse event connected to a compounded peptide would likely activate litigation, congressional inquiry, and state action; the 2023 concerns define the exposure that a non-enforcement posture increases. Mitigation depends on the data mechanism working as intended; absent that, the policy’s trigger events could be defined in advance.
The policy moves residual risk to users and to state and civil liability systems at the same time it withholds the federal approval judgment. The guardrails mitigate, but the underlying determination is absent by design. A public communication stating that the covered products have not received a safety-and-effectiveness determination would prevent an enforcement preference from being mistaken for an endorsement.
How this is being framed
The policy’s form is best explained by statutory authority and institutional process rather than by market demand or scientific evidence. The directive resolves the procedural dispute over instrument — a formal regulation declaring the substances safe, or a directive not to enforce — in favor of the department’s leadership, while the underlying scientific disagreement persists and the legal status of the products themselves is untouched. It is a safe harbor grounded in discretion rather than in a scientific determination. Both the “step back” characterization and the “avoids a direct confrontation” framing derive from people familiar with the process, not from HHS itself; the department did not respond to a request for comment.
Reporting and verification status
The reporting is by the Associated Press as carried by The Guardian, with a publication date of October 28, 2026. External verification status: the 2023 compounding-exclusion list and the Kennedy “big fan”/BPC-157 remarks are article-supported, with external verification unresolved (no relevant open-web excerpts returned either way); the July meeting characterization is independently confirmed by AP and PBS carrying AP reporting; the 2012 outbreak linkage is independently confirmed by CDC MMWR and additional open-web sources. The article supplies no year for the “July” meeting; none is added. The HHS policy document’s exact posting date, the full list of peptides it covers, and whether the side-effect reporting requirement specifies a submission mechanism and deadline were not independently reviewable in the source material.
Analytical techniques used in this piece
This analysis applies the methods below. Each links to a short, plain-English explainer you can read and reuse.
- Interest Mapping
- Separates parties’ stated positions from their underlying interests (Fisher & Ury).
- Red-Team Assessment
- Models a capable adversary probing a plan for the seams they would exploit.
- Root-Cause Analysis
- Traces a symptom back along its causal chain to the conditions that actually generated it.